LYON, France--(BUSINESS WIRE)--Flamel Technologies, SA (Nasdaq: FLML) today announced that it has entered into agreements with a leading global healthcare provider to assess the applicability of the Medusa® platform for controlled release formulations of therapeutic proteins. The Company will receive technology access fees totaling € 2.5 million pursuant to these agreements, plus full development costs for the program. A joint press release regarding the agreement is anticipated for release in mid July.
